Donanemab, the second drug against Alzheimer's disease, has been approved in the US. It is designed to slow the progression of dementia, reports the Daily Mail. Donanemab aims to remove aggregates of the protein beta-amyloid. These structures are believed to be responsible for nerve cell loss and the symptoms of Alzheimer's disease. Clinical trials have shown that the drug can slow brain deterioration by up to 35%. After a year and a half, those taking the drug had 84% fewer amyloid aggregates compared to the placebo group. The drug is administered intravenously once a month. One vial will cost $695. Despite the breakthrough in treating Alzheimer's disease, experts have expressed concern about Donanemab because of the risk of brain hemorrhages. These led to several fatalities during the study. Twenty-five percent developed cerebral edema. The drug Lekanemab, which is already used to treat patients with Alzheimer's disease, was previously approved in the US.